Related Experiment Videos
A prospective, randomized clinical trial of universal WBC reduction
W H Dzik1, J K Anderson, E M O'Neill
1Blood Transfusion Service, Massachusetts General Hospital, Boston 02114, USA. sdzik@partners.org
Transfusion
|November 15, 2002
Summary
Universal white blood cell (WBC) reduction in transfusions did not show benefits over selective reduction. This study found no significant differences in mortality, hospital length of stay, or costs for patients receiving WBC-reduced blood components.
Area of Science:
- Transfusion Medicine
- Hematology
- Clinical Trials
Background:
- Exposure to allogeneic donor white blood cells (WBCs) can cause transfusion complications in specific patient populations.
- The universal application of WBC reduction in blood transfusions remains a controversial topic in clinical practice.
Purpose of the Study:
- To evaluate the clinical and economic impact of converting to universal WBC reduction in a general hospital setting.
- To determine if universal WBC reduction offers advantages over selective WBC reduction for transfusion recipients.
Main Methods:
- A randomized, controlled clinical trial was conducted involving 2780 eligible patients requiring transfusion.
- Patients were randomly assigned to receive either unmodified blood components or WBC-reduced red blood cells (RBCs) and platelets.
- Exclusion criteria included patients with existing medical indications for WBC-reduced blood; analysis was limited to the first hospitalization.
Main Results:
- No significant differences were observed between the universal WBC reduction and control groups in primary outcomes: in-hospital mortality (9.0% vs. 8.5%), hospital length of stay (6.3 vs. 6.4 days), and total hospital costs ($19,200 vs. $19,500).
- Secondary outcomes, including intensive care unit length of stay, postoperative length of stay, antibiotic usage, and readmission rates, also showed no significant differences.
- Subgroup analyses by patient demographics, transfusion volume, or surgical category did not reveal any benefit of universal WBC reduction, although a trend towards fewer febrile reactions was noted in the WBC-reduced group (p=0.06).
Conclusions:
- The conversion from selective to universal WBC reduction did not demonstrate a significant beneficial effect in the studied general hospital population.
- Current evidence does not support the universal implementation of WBC reduction based on the outcomes measured in this trial.